Anecortave acetate therapy shows potential for OAG
August 1st 2006Fort Lauderdale, FL-Anecortave acetate (Retaane, Alcon Laboratories) is a potential new therapy for open-angle glaucoma (OAG) that seems to be highly effective, with a mean 25% decrease in IOP 6 months after one anterior juxtascleral injection, Alan L. Robin, MD, reported at the annual meeting of the Association for Research in Vision and Ophthalmology.
Advice for first-year residents
August 1st 2006First-year residents, welcome to ophthalmology, by far the best field in medicine! The next 3 years are going to be exhilarating, nerve-wracking, fun, and will go by way too fast. The first few days and weeks can be the most stressful, especially since many of us come from medical school and internship without even the basics of ophthalmology know-how (we couldn't even do a basic ophtho exam on our first day!).
Patients with DME have response to fluocinolone acetonide intravitreal implant in study outcomes
August 1st 2006Fort Lauderdale, FL-A fluocinolone acetonide intravitreal implant led to an improvement in visual acuity of 3 or more lines at 36 months in a significant proportion of patients with diabetic macular edema (DME) enrolled in a multicenter clinical trial.
Rheopheresis may be useful in dry AMD
August 1st 2006Fort Lauderdale, FL-In a small open-label trial of rheopheresis therapy (RHEO, Occulogix) for the treatment of dry age-related macular degeneration (AMD), patients who did not have elevated levels of certain macromolecules demonstrated visual results similar to those of patients in a separate study who had significantly elevated levels of macromolecules such as fibrinogen, IgA, and total cholesterol.
Regression of proliferative diabetic retinopathy drmatic
August 1st 2006Fort Lauderdale, FL-Intravitreal injection of pegaptanib sodium (Macugen, OSI/Eyetech Pharmaceuticals/Pfizer) was well tolerated and effective in reducing the progression of proliferative diabetic retinopathy (PDR) in all 10 eyes of 10 patients in a small experimental study. Regression of neovascularization was seen as early as the first follow-up examination 3 weeks after the initial injection, said Victor H. Gonzalez, MD, who is in private practice with the Valley Retina Institute in McAllen, TX.
High-speed, high-resolution imaging of eye in sight
August 1st 2006Fort Lauderdale, FL-Ultra-high-speed, ultra-high-resolution spectral-domain optical coherence tomography (SD-OCT) seems to have surpassed the slow-speed, low-resolution OCT and provides video images of the minute structural changes in the glaucomatous eye.
High-quality, real-time views of retina possible
August 1st 2006Fort Lauderdale, FL-Researchers have developed a new-generation adaptive optics scanning laser ophthalmoscope (AOSLO) that can produce high-fidelity, real-time microscopic views of the living human retina. The device has been tested and found to be effective on both healthy and diseased eyes, said Yuhua Zhang, PhD, a researcher at the School of Optometry, University of California, Berkeley.
Benefits of ranibizumab maintained over 2 years
August 1st 2006Fort Lauderdale, FL-The agent ranibizumab (Lucentis, Genentech)-which was approved by the FDA for the treatment of wet age-related macular degeneration (AMD) on June 30 (see in this issue)-appears to be both safe and effective, according to 2-year data from the MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab In the Treatment of Neovascular AMD)study.
Oral agent reduces risk of vision loss in diabetic retinopathy in analysis
August 1st 2006Fort Lauderdale, FL-Treatment with ruboxistaurin mesylate (RBX, Eli Lilly Co.) reduced the risk of sustained moderate vision loss by 41% in patients with moderately severe to very severe nonproliferative diabetic retinopathy compared with placebo, according to a combined analysis of two studies.
London welcomes ESCRS annual congress attendees
August 1st 2006London-The XXIV Annual Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) is scheduled to begin Saturday, Sept. 9 and continue until Wednesday, Sept. 13 in this cosmopolitan capital on the Thames River. Most of the symposia and courses will be held at the ExCel London International Exhibition and Conference Center, London.
Advanced surface ablation: future of refractive surgery?
August 1st 2006San Francisco-Advanced surface ablations, such as LASEK and Epi-LASIK, are ideal refractive procedures for challenging cases, such as patients with thin corneas and high myopia, and are even better for routine cases, according to Richard W. Yee, MD.
ZaBeCor, Acuity develop anti-inflammatory agent
August 1st 2006Philadelphia-Acuity Pharmaceuticals and ZaBeCor Pharmaceutical Co. entered into a license option agreement in which Acuity gains exclusive development and commercialization rights to ophthalmic applications of a small interfering RNA (siRNA).
Dr. Kang Zhang honored with ASCI membership
August 1st 2006Salt Lake City-The American Society of Clinical Investigators (ASCI)-one of the oldest and most prestigious medical honor societies in the United States-has selected Kang Zhang, MD, PhD, as a member. Dr. Zhang is only the second ophthalmologist in the organization's 98-year history to be honored with membership.
OSI/Eyetech announces management changes
August 1st 2006Melville, NY-OSI Pharmaceuticals Inc. announced management changes to its OSI/ Eyetech Pharmaceuticals business team. Paul G. Chaney, chief operating officer of OSI/Eyetech, has been promoted to the role of executive vice president, OSI Pharmaceuticals, and president of OSI/Eyetech.
WaveLight laser gets nod for mixed astigmatism
August 1st 2006Sterling, VA-WaveLight Inc.'s wavefront-optimized Allegretto Wave excimer laser system received approval by the FDA for the treatment of mixed astigmatism. The laser is used to reduce or eliminate naturally occurring mixed astigmatism of up to 6 D at the spectacle plane.
Alcon IOL receives NTIOL designation
August 1st 2006Fort Worth, TX-The Centers for Medicare and Medicaid Services' (CMS) New Technology Intraocular Lens (NTIOL) classification of Reduced Spherical Aberration has been applied to the AcrySof IQ IOL (Alcon Laboratories). The IOL gained inclusion by proving the same or greater clinical benefit as the lens that established the NTIOL subset, according to Alcon Laboratories.
Bimatoprost 0.03% solution rreceives approval as first-line treatment
August 1st 2006Irvine, CA-The FDA's new indication of bimatoprost ophthalmic solution 0.03% (Lumigan, Allergan) from a second- to a first-line treatment for elevated IOP expands the options to ophthalmologists who commonly treat open-angle glaucoma or ocular hypertension.
Numerous risk factors found for corneal ectasia after LASIK
August 1st 2006San Francisco-Knowledge about risk factors for corneal ectasia after LASIK is increasing, and some of the risk factors may be very subtle. R. Doyle Stulting, MD, PhD, described some of these risks factors during Cornea Day 2006 at the annual meeting of the American Society of Cataract and Refractive Surgery.
Epithelial delay, pain are concerns with new NSAID
July 15th 2006Fort Lauderdale, FL-Administration of nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories) for epithelial healing and pain control resulted in delayed healing in patients who had undergone surface ablation, according to a report by Marguerite B. McDonald, MD, FACS, and William Trattler, MD, that was presented at the annual meeting of the Association for Research and Vision in Ophthalmology.
Topical NSAID dosed b.i.d. effectively treats macular edema following cataract surgery
July 15th 2006Fort Lauderdale, FL-The new b.i.d. dosed topical non-steroidal anti-inflammatory drug (NSAID) bromfenac ophthalmic solution 0.09% (Xibrom, Ista Pharmaceuticals), was found to be as effective as either diclofenac sodium 0.1% ophthalmic solution (Voltaren, Novartis Ophthalmics) or ketorolac tromethamine 0.5% (Acular, Allergan) ophthalmic solution dosed q.i.d. in a recent study of acute pseudophakic cystoid macular edema (CME) treatment following uncomplicated cataract surgery.